FDA
-
-
-
-
-
-
-
Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023
-
-
-
-
-
-
-
Aravive Appoints Carolina Petrini as Chief Commercial Officer
-
-
-
-
-
-
-
Aravive To Participate in Piper’s 34th Annual Healthcare Conference
-
-
-
-
-
-
-
Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference
-
-
-
-
-
-
-
Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)
-
-
-
-
-
-
-
Aravive Inc. (ARAV) Prices 4.85M Share and Warrant Direct Offering
-
-
-
-
-
-
-
Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting
-
251,890 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All